Abacavir/3TC vs. Tenofovir/FTC — Published Results from ACTG 5202

Virologic failures and serious adverse events were more common with abacavir/3TC than with tenofovir/FTC among patients with high viral loads at screening. But the data are incomplete, and some are quite perplexing.

From September 2005 to November 2007, ACTG investigators enrolled 1858 HIV-infected, treatment-naive adults into a randomized trial comparing four once-daily antiretroviral regimens that consisted of abacavir/3TC or tenofovir/FTC, plus either efavirenz or ritonavir-boosted atazanavir. (NRTI use was blinded; the other drugs were not.) In February 2008, a scheduled interim analysis showed that, among patients with screening viral loads ≥100,000 copies/mL, abacavir/3TC was associated with higher rates of virologic failure and serious adverse events than tenofovir/FTC (JW AIDS Clin Care Mar 10 2008). This finding led to a change in study protocol and also influenced revisions to the U.S. Department of Health and Human Services (DHHS) treatment …

Reviewing Author

Abigail Zuger, MD

Disclosures

Nothing to disclose

Abigail Zuger, MD

Disclosures

Nothing to disclose

Abacavir/3TC vs. Tenofovir/FTC — Published Results from ACTG 5202

Topics

Reviewing Author